HIGHLIGHTS
- who: Pooja Gangras and colleagues from the Lilly Institute for Genetic Medicine, Eli Lilly and Company, Indianapolis, IN, USA have published the research: Investigating SH-SY5Y Neuroblastoma Cell Surfaceome as a Model for Neuronal-Targeted Novel Therapeutic Modalities, in the Journal: (JOURNAL)
- what: A lot of the ongoing research in the field of novel modalities is focused on investigating cell type-specific delivery to achieve higher efficacy at lower drug doses while lowering the risk of off-target effects and toxicity. The authors focus on investigating the SH-SY5Y cell line as a model for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.